“Global Radioligand Therapy Market to Reach $16,658.4 Million by 2031”
FEATURED COMPANIES
- Bayer AG
- Clovis Oncology
- Curium Pharma
- Fusion Pharma
- Molecular Partners
- Novartis International AG
The global radioligand therapy market was valued at $9,754.9 million in 2020 and is projected to reach $16,658.4 million by 2031, reveals the premium market intelligence study by the publisher. The study also highlights that the market is set to witness a CAGR of 4.67% during the forecast period 2021-2031.
Market share analysis of key market players
Growth share analysis of companies
Impact of COVID-19 on the global radioligand therapy market
Growth analysis by indication, product, biomarker, and region
Detailed company and product profiling for 16 companies
Pipeline analysis for potential pipeline drugs
Besides these parameters, the study also encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.
This study indicates that the growing prevalence of cancer, strategic initiatives by key market players, and rise in microbial sequencing are the major factors anticipated to contribute to the growth of the global radioligand therapy market.
Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market segmented based on indication, product, biomarker, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.
Key insights are drawn from in-depth interviews with the key opinion leaders of 16 leading companies, market participants, and vendors. Key players operating in the global radioligand therapy market include Johnson & Johnson Services Inc., Pfizer Inc., Amneal Pharmaceuticals, Novartis International AG, Point Biopharma Global Inc., Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings Inc. (Progenix Pharmaceuticals), Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Curium Pharma, Precirix, and RadioMedix.
In the comprehensive study of the global radioligand therapy market, the publisher extensively covers the following:
Market numbers on micro-segments influencing the marketMarket share analysis of key market players
Growth share analysis of companies
Impact of COVID-19 on the global radioligand therapy market
Growth analysis by indication, product, biomarker, and region
Detailed company and product profiling for 16 companies
Pipeline analysis for potential pipeline drugs
Besides these parameters, the study also encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.
This study indicates that the growing prevalence of cancer, strategic initiatives by key market players, and rise in microbial sequencing are the major factors anticipated to contribute to the growth of the global radioligand therapy market.
The study highlights the following in the report:
- Emerging opportunities in the radioligand therapy market
- Impact of COVID-19 on the global radioligand therapy market
- Market scenario for radioligand therapy marketed products and potential pipeline products
- Drivers promoting the growth of the market
Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market segmented based on indication, product, biomarker, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.
Key insights are drawn from in-depth interviews with the key opinion leaders of 16 leading companies, market participants, and vendors. Key players operating in the global radioligand therapy market include Johnson & Johnson Services Inc., Pfizer Inc., Amneal Pharmaceuticals, Novartis International AG, Point Biopharma Global Inc., Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings Inc. (Progenix Pharmaceuticals), Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Curium Pharma, Precirix, and RadioMedix.
Who should buy this report?
- Manufacturers of radioligand therapy-approved products and potential pipeline products
- Pharmaceutical and biotechnology companies
- Research and academic institutions
How can market intelligence on radioligand therapy market add value to an organization’s decision-making process?
- Aids in product development
- Helps in targeting a segment for launching and approval of a new product
- Offers go-to-market strategies for the different product categories
- Supports in diversifying the product portfolio based on unmet needs
- Helps in analyzing technological substitutes and compares the specification
- Helps to adjust the pricing of upcoming products
- Assists in exploring the newer applications
- Supports in analyzing the competitors’ funding scenario
Insightful Questions Covered to Enable Companies Take Strategic Decisions
- How is radioligand therapy revolutionizing oncology?
- What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
- What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
- How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
- What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
- What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
- What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
- How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
- Products (Approved Products and Potential Pipeline)
- Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
- Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
- Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
- What are the growth opportunities for the radioligand therapy companies in the region of their operation?
- Who are the leading players with significant offerings in the global radioligand therapy market?
- Which companies are anticipated to be highly disruptive in the future, and why?
Frequently Asked Questions about the Global Radioligand Therapy Market
What is the estimated value of the Global Radioligand Therapy Market?
What is the growth rate of the Global Radioligand Therapy Market?
What is the forecasted size of the Global Radioligand Therapy Market?
Who are the key companies in the Global Radioligand Therapy Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Bayer AG
- Clovis Oncology
- Curium Pharma
- Fusion Pharma
- Molecular Partners
- Novartis International AG
1 Research Methodology
2 Radioligand Therapy Market
3 Industry Analysis
4 Pipeline Analysis
5 Market Dynamics
6 Competitive Landscape
7 Global Radioligand Therapy Market, Indication, $Million, 2020-2031
8 Global Radioligand Therapy Market, Products, $Million, 2020-2031
9 Global Radioligand Therapy Market, Biomarker, $Million, 2020-2031
10 Global Radioligand Therapy Market, Region, $Million, 2020-2031
11 Markets - Competitive Benchmarking & Company Profiles
12 Emerging Company Profiles.
List of Figures
List of Tables
Note: Product cover images may vary from those shown
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals LLC
- Novartis International AG
- POINT Biopharma Global Inc
- Fusion Pharma
- Clovis Oncology
- Telix Pharmaceuticals
- Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
- Bayer AG
- Molecular Partners
- ITM Isotope Technologies Munich SE
- Curium Pharma
- Precirix
- Radio Medix
Note: Product cover images may vary from those shown